Avicanna Subsidiary Completes Export of CBD Dominant Cannabis Flower into Switzerland
Avicanna (OTCQX: AVCNF), through its subsidiary Santa Marta Golden Hemp SAS (SMGH), has completed its first export of non-psychoactive CBD dominant cannabis flower to Switzerland. This milestone marks SMGH's first organic certified flower export and represents the 20th international market for Aureus-branded products and 23rd market for all Avicanna products.
The export follows the company's 2024 infrastructure and practice improvements at SMGH, aimed at expanding its Aureus-branded premium organic flower portfolio. The shipment included three proprietary cannabis varieties registered in Colombia, targeting growing demand in European and Australian medical cannabis markets.
Avicanna (OTCQX: AVCNF), tramite la sua controllata Santa Marta Golden Hemp SAS (SMGH), ha effettuato la prima esportazione di infiorescenze di cannabis a predominanza di CBD non psicoattivo in Svizzera. Questo traguardo rappresenta la prima esportazione di fiori biologici certificati da parte di SMGH e segna il 20° mercato internazionale per i prodotti a marchio Aureus e il 23° mercato per l'intera gamma di prodotti Avicanna.
L'invio arriva dopo gli interventi di miglioramento delle infrastrutture e delle pratiche operativi realizzati nel 2024 presso SMGH, volti ad ampliare il portafoglio di fiori premium biologici a marchio Aureus. La spedizione comprendeva tre varietà proprietarie di cannabis registrate in Colombia, studiate per soddisfare la crescente domanda nei mercati della cannabis medica in Europa e in Australia.
Avicanna (OTCQX: AVCNF), a través de su filial Santa Marta Golden Hemp SAS (SMGH), ha completado su primera exportación a Suiza de flor de cannabis dominante en CBD no psicoactivo. Este hito constituye la primera exportación de flor orgánica certificada por parte de SMGH y marca el 20.º mercado internacional para los productos de la marca Aureus y el 23.º mercado para todos los productos de Avicanna.
La exportación se produce tras las mejoras en infraestructura y prácticas implementadas en 2024 en SMGH, destinadas a ampliar su portafolio de flores orgánicas premium bajo la marca Aureus. El envío incluyó tres variedades de cannabis propietarias registradas en Colombia, dirigidas a la creciente demanda en los mercados de cannabis medicinal de Europa y Australia.
Avicanna (OTCQX: AVCNF)는 자회사 Santa Marta Golden Hemp SAS(SMGH)를 통해 스위스로 정신작용이 없는 CBD 우세 대마 꽃의 첫 수출을 완료했습니다. 이 성과는 SMGH의 첫 유기농 인증 꽃 수출이며 Aureus 브랜드 제품의 20번째 국제 시장 및 Avicanna 전체 제품의 23번째 시장 진출을 의미합니다.
이번 수출은 2024년 SMGH에서 진행된 인프라 및 운영 관행 개선에 따른 것으로, Aureus 프리미엄 유기농 꽃 포트폴리오 확대를 목표로 했습니다. 선적에는 콜롬비아에 등록된 세 가지 독점 대마 품종이 포함되어 유럽 및 호주의 의료용 대마 시장에서 증가하는 수요를 겨냥했습니다.
Avicanna (OTCQX: AVCNF), via sa filiale Santa Marta Golden Hemp SAS (SMGH), a réalisé sa première exportation de fleurs de cannabis riches en CBD et non psychoactives vers la Suisse. Cette étape constitue la première exportation de fleurs certifiées biologiques par SMGH et représente le 20e marché international pour les produits de la marque Aureus et le 23e marché pour l'ensemble des produits Avicanna.
Cette exportation intervient après les améliorations infrastructurelles et opérationnelles effectuées en 2024 chez SMGH, visant à élargir son portefeuille de fleurs biologiques premium sous la marque Aureus. L'expédition comprenait trois variétés propriétaires de cannabis enregistrées en Colombie, destinées à répondre à la demande croissante des marchés du cannabis médical en Europe et en Australie.
Avicanna (OTCQX: AVCNF) hat über seine Tochtergesellschaft Santa Marta Golden Hemp SAS (SMGH) die erste Ausfuhr von nicht-psychoaktivem, CBD-dominiertem Cannabisblüten nach Schweiz abgeschlossen. Dieser Meilenstein ist SMGHs erste zertifizierte Bio-Blüten-Exportlieferung und markiert den 20. internationalen Markt für Aureus-Produkte sowie den 23. Markt für alle Avicanna-Produkte.
Der Export folgt auf Infrastruktur- und Verfahrensverbesserungen bei SMGH im Jahr 2024, die darauf abzielen, das Aureus-Portfolio an hochwertigen, biologischen Blüten zu erweitern. Die Sendung enthielt drei proprietäre Cannabissorten, in Kolumbien registriert, um der steigenden Nachfrage in den medizinischen Cannabismärkten Europas und Australiens gerecht zu werden.
- None.
- None.
This marks the first export of organic certified flower for SMGH, 20th international market for Aureus branded products and 23rd market for all Avicanna products
TORONTO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that through its majority-owned subsidiary Santa Marta Golden Hemp SAS the Company completed the first export of non-psychoactive CBD dominant cannabis flower to Switzerland.
This export is a result of improvements directed by the Company in 2024, when it improved internal practices and enhanced the local infrastructure at SMGH to expand the portfolio of Aureus branded products with premium organic flower to meet the growing demand of medical cannabis flower in Europe and Australia. The Company is currently producing a range of proprietary and premium CBD, CBG and THC genetics for these markets.
This export included three proprietary varieties which are a part of the Company’s portfolio of registered cannabis varieties in Colombia. This also marks the 20th international market for Aureus-branded products and 23rd market for all Avicanna products which further validates the Company’s expertise in navigating complex regulatory processes for its commercialization efforts internationally.
Avicanna carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.
About Aureus™
The Aureus™ brand is the Company’s line of raw materials and active pharmaceutical ingredients (“API”), including CBD, CBG and THC manufactured through SMGH. The cannabis raw materials supplied by SMGH, form part of the Company’s supply chain and reliable input for its consumer retail, medical cannabis, and pharmaceutical preparations and pipeline globally.
SMGH is also dedicated to providing consistent, high-quality sources of input materials to the various companies operating in a variety of industries internationally. SMGH received Good Agricultural, and Collection Practices (“GACP”) and Organic certifications under the United States Department of Agriculture National Organic Program (“USDA”) for its hemp cultivars. SMGH has exported Aureus™ branded products into 20 different countries for research and manufacturing purposes. The SMGH facility contains approximately 300,000 Square feet of cultivation space with an extraction capacity of 300kg. The current annual yield is approximately 26,400 kg.
About Avicanna:
Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars.
- Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto™ is an established brand in Canada currently available nationwide across several channels and expanding into new international markets.
- Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the medical cannabis patients’ journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens.
- Pharmaceutical pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain, and various neurological disorders.
- Active pharmaceutical ingredients (Aureus Santa Marta™): Active pharmaceutical ingredients supplied by the Company’s majority owned subsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the Company’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. SMGH also forms part of the Company’s supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally.
SOURCE Avicanna Inc.
Stay Connected
For more information about Avicanna, visit our website or contact Ivana Maric by email at info@avicanna.com.
Cautionary Note Regarding Forward-Looking Information and Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements related to the Company’s future business operations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 11, 2025, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9184ce8a-19da-44f5-99c4-fdc0bc66ea7f
FAQ
What milestone did Avicanna (AVCNF) achieve in Switzerland?
How many international markets does Avicanna now serve with its products?
What improvements did Avicanna make to facilitate this export?
What types of cannabis varieties did Avicanna export to Switzerland?
